Use of docetaxel (Taxotere®) in patients with paclitaxel (Taxol®) hypersensitivity

被引：32

作者：

Moon, C ^{[1
]}

Verschraegen, CF ^{[1
]}

Bevers, M ^{[1
]}

Freedman, R ^{[1
]}

Kudelka, AP ^{[1
]}

Kavanagh, JJ ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Internal Med Specialities, Sect Gynecol & Med Therapeut, Houston, TX 77030 USA

来源：

ANTI-CANCER DRUGS | 2000年 / 11卷 / 07期

关键词：

allergic reactions; ovarian neoplasms; taxane;

D O I：

10.1097/00001813-200008000-00007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Anaphylaxis or significant hypersensitivity reaction is one of the most catastrophic potential complications of chemotherapy. There is a 2-5% risk of hypersensitivity with paclitaxel, a commonly used chemotherapeutic agent for various cancers. Three patients, who developed hypersensitivity to paclitaxel infusion, received docetaxel without allergic reactions. Docetaxel may therefore be an alternative treatment for patients with paclitaxel hypersensitivity. [(C) 2000 Lippincott Williams & Wilkins].

引用

页码：565 / 568

页数：4

共 50 条

[41] COPING WITH TOXICITIES OF DOCETAXEL (TAXOTERE(TM))
SCHRIJVERS, D
WANDERS, J
DIRIX, L
PROVE, A
VONCK, I
VANOOSTEROM, A
KAYE, S
ANNALS OF ONCOLOGY, 1993, 4 (07) : 610 - 611
[42] Toxic dermatitis in patients treated with Taxotere (docetaxel): Three case reports
von Stebut, E.
Steinbrink, K.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2011, 49 (01) : 1 - 2
[43] ENANTIOSELECTIVE SYNTHESIS OF THE TAXOL AND TAXOTERE SIDE-CHAINS
KOSKINEN, AMP
KARVINEN, EK
SIIRILA, JP
JOURNAL OF THE CHEMICAL SOCIETY-CHEMICAL COMMUNICATIONS, 1994, (01) : 21 - 22
[44] The Effect of Docetaxel (Taxotere (R)) on Human Gastric Cancer Cells Exhibiting Low-Dose Radiation Hypersensitivity
Balcer-Kubiczek, Elizabeth K.
Attarpour, Mona
Wang, Jian Z.
Regine, William F.
CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2008, 2 : 301 - 311
[45] DEXAMETHASONE USE TO PREVENT PACLITAXEL HYPERSENSITIVITY REACTIONS
Glenn, Sarah
ONCOLOGY NURSING FORUM, 2020, 47 (02)
[46] TAXOL AND TAXOTERE - CURRENT STATUS AND FUTURE-PROSPECTS
BISSETT, D
KAYE, SB
EUROPEAN JOURNAL OF CANCER, 1993, 29A (09) : 1228 - 1231
[47] Docetaxel (Taxotere): Preclinical and general clinical information
Earhart, RH
SEMINARS IN ONCOLOGY, 1999, 26 (05) : 8 - 13
[48] Subungueal Haemorrhages Following Docetaxel (Taxotere) Treatment
Fenniche, Samy
Hammami, Houda
Badri, Talel
Mokhtar, Insaf
Benmously, Rym
CURRENT DRUG SAFETY, 2012, 7 (03) : 247 - 249
[49] Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin)
Burris, HA
SEMINARS IN ONCOLOGY, 2000, 27 (02) : 19 - 23
[50] Recent progress in the clinical development of docetaxel (Taxotere)
Hortobagyi, GN
SEMINARS IN ONCOLOGY, 1999, 26 (03) : 32 - 36

← 1 2 3 4 5 →